Biontech Se Sponsored Adr Stock News

The stock price of BioNTech SE (NASDAQ: BNTX) increased by 4.37% in the most recent trading session. This is why it happened.

If approved, Pfizers vaccine would be the first available for American children under the age of five Pfizer and BioNTech announced on Tuesday that they were seeking approval from the US Food and Drug Administration (FDA) to vaccinate children as young as 6 months old against Covid-19. If given approval, children aged six months to

US regulators are considering the first COVID-19 vaccine for children under the age of 5, the only age group not yet eligible for the shots, after Pfizer Inc and BioNTech SE began the regulatory approval process on Tuesday, February 1. A decision is expected as soon as this month. The companies said they began submitting data for an emergency use authorization even though they did not meet a key target in their clinical trial of 2- to 4- year olds. They are submitting the data at the request of the US Food and Drug Administration in order to address an urgent public health need in the age group, they said. The arrival of a vaccine for younger children could help harried parents who have had to contend with quarantines and closures of pre-schools and daycare centers. Having a safe and effective vaccine available for children in this age group is a priority, acting FDA Commissioner Janet Woodcock said. She said the agency asked for the application because of the recent Omicron surge. The FDA said an outside committee of expert advisers would meet on February 15 to discuss the authorization.

For kids under 5, Pfizer''s study is giving participants two shots three weeks apart, followed by a third dose at least two months later. The company is testing whether the youngsters produce antibody levels similar to those known to protect teens and young adults.

Pfizer and BioNTech have sought approval from the US Food and Drug Administration (FDA) to vaccinate children under five against Covid-19 Read Full Article at RT.com

Pfizer Inc and BioNTech SE on Tuesday said they have begun submitting data to US regulators seeking emergency use authorisation (EUA) of their COVID-19 vaccine for children under age 5, despite weaker-than-expected immune responses in their clinical trial of 2- to 4-year-olds. The companies said they

In a Tuesday press release, the FDA said the agency pushed Pfizer and BioNTech to submit the application given the ongoing Omicron surge.

In a Tuesday press release, the FDA said the agency pushed Pfizer and BioNTech to submit the application given the ongoing Omicron surge.

BioNTech and Pfizer could be about to file for authorization of their vaccine for younger kids.

Pfizer Inc and Germany''s BioNTech SE are expected to submit an emergency use authorisation request as early as Tuesday to the US Food and Drug Administration (FDA) for vaccines for children aged six months to 5 years, the Washington Post reported.

Pfizer and Germany''s BioNTech are expected to submit an emergency use authorization request on Tuesday to the U.S. Food and Drug Administration for vaccines for children aged six months to 5 years, the Washington Post reported on Monday.

Federal regulators are expected to be asked as soon as Tuesday to authorize Pfizer's COVID-19 vaccine for children as young as 6 months old, and the first shots could come by the end of February, acco

Pfizer Inc PFE and BioNTech SE BNTX are likely to submit a request for an emergency use authorization to the U.S. Food and Drug Administration on Tuesday for a COVID-19 vaccine aimed at children young

A Pfizer-BioNTech two-shot regimen for younger kids could be ready in the coming weeks, people briefed on the situation told the outlet on Monday.

Shares of Novavax Inc. rallied 10.0% in trading on Monday after the company said it filed for authorization of its experimental COVID-19 shot in the U.S. Novavax''s COVID-19 vaccine candidate is protein-based, meaning it''s a different type of vaccine than the mRNA shots developed by BioNTech SE /Pfizer Inc. and Moderna Inc. or the Johnson & Johnson viral vector vaccine. Novavax said it is seeking authorization for its two-dose vaccine in adults, based on two clinical studies. One Phase 3 trial assessing the vaccine in about 15,000 adults in the U.K. reported an 89.7% efficacy rate against infection with the virus, according to research published in the New England Journal of Medicine in September. A second trial that enrolled about 30,000 adults in the U.S. and Mexico found that shots produced an efficacy rate of 92.6% against any variants of concern or interest. That study was also published in the New England Journal of Medicine, in December. Some of the vaccine''s side effects include headache, pain at the injection site, and fatigue.